Published in Bioessays on January 01, 1999
Dual roles of Cripto as a ligand and coreceptor in the nodal signaling pathway. Mol Cell Biol (2002) 1.80
Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg (2002) 1.79
Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells. Mol Cell Biol (2002) 1.53
Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells. J Cell Biol (2003) 1.52
mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. Genome Biol (2009) 1.34
Cripto promotes A-P axis specification independently of its stimulatory effect on Nodal autoinduction. J Cell Biol (2008) 1.01
Msx2 induces epithelial-mesenchymal transition in mouse mammary epithelial cells through upregulation of Cripto-1. J Cell Physiol (2009) 0.98
Dominant negative Ras enhances lactogenic hormone-induced differentiation by blocking activation of the Raf-Mek-Erk signal transduction pathway. J Cell Physiol (2004) 0.85
A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization. J Exp Med (1970) 15.86
Studies of the macrophage complement receptor. Alteration of receptor function upon macrophage activation. J Exp Med (1975) 7.87
Binding of sheep red blood cells to a large population of human lymphocytes. Nature (1971) 7.67
Enhanced binding of neuraminidase-treated sheep erythrocytes to human T lymphocytes. Blood (1973) 4.99
Receptors for cold-insoluble globulin (plasma fibronectin) on human monocytes. J Exp Med (1981) 3.93
Characterization of the macrophage receptro for complement and demonstration of its functional independence from the receptor for the Fc portion of immunoglobulin G. J Exp Med (1975) 3.80
Theta-bearing and complement-receptor lymphocytes are distinct populations of cells. Science (1971) 3.16
Mechanism of binding of soluble immune complexes to lymphocytes. Cell Immunol (1973) 2.93
Studies on the selective lysis and purification of Trypanosoma cruzi. J Exp Med (1975) 2.54
Cell surface immunoglobulin. IV. Distribution among thymocytes, bone mrrow cells, and their derived populations. J Exp Med (1972) 2.50
The induction of macrophage spreading: role of coagulation factors and the complement system. J Exp Med (1976) 2.41
Tissue localization of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. Proc Natl Acad Sci U S A (1970) 2.29
Increased proportion of complement-receptor lymphocytes in the peripheral blood of patients with chronic lymphocytic leukemia. Blood (1972) 2.25
Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG (2012) 2.14
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer (2006) 1.85
Bone marrow origin of complement-receptor lymphocytes. Eur J Immunol (1971) 1.80
Copper induction of laccase isoenzymes in the ligninolytic fungus Pleurotus ostreatus. Appl Environ Microbiol (2000) 1.69
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer (2003) 1.67
Immune phagocytosis in murine malaria. J Exp Med (1979) 1.66
Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology (2000) 1.64
The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets (2005) 1.59
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol (2007) 1.52
A novel white laccase from Pleurotus ostreatus. J Biol Chem (1997) 1.52
The induction of macrophage spreading by factor B of the properdin system. J Exp Med (1979) 1.50
The role of EGF-related peptides in tumor growth. Front Biosci (2001) 1.45
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Complement receptors. Contemp Top Mol Immunol (1977) 1.44
Concurrent nitroglycerin administration reduces the efficacy of recombinant tissue-type plasminogen activator in patients with acute anterior wall myocardial infarction. Am Heart J (1995) 1.39
Measures to decrease the risk of acquired immunodeficiency syndrome transmission by blood transfusion. Evidence of volunteer blood donor cooperation. Transfusion (1985) 1.36
Autopsy findings in 111 cases of esophageal cancer. Cancer (1981) 1.34
Regulation of macrophage migration by products of the complement system. Proc Natl Acad Sci U S A (1979) 1.29
C3 split products inhibit the binding of antigen-antibody-complement complexes to B lymphocytes. J Immunol (1973) 1.28
A population of lymphocytes bearing a membrane receptor antigen-antibody-complement complexes. II. Specific isolation. Cell Immunol (1971) 1.27
Leukemic cells with membrane properties of thymus-derived (T) lymphocytes in a case of Sézary's syndrome: morphologic and immunologic studies. Clin Immunol Immunopathol (1973) 1.27
Monocyte receptors for fibronectin characterized by a monoclonal antibody that interferes with receptor activity. J Exp Med (1985) 1.25
The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer. Endocr Relat Cancer (2000) 1.22
Spectrum of clinical variability in familial deletion 22q11.2: from full manifestation to extremely mild clinical anomalies. Clin Genet (2003) 1.18
Interaction and release of soulble immune complexes from mouse B luymphocytes. Cell Immunol (1973) 1.14
Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Med Oncol (2011) 1.14
Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment. Arthritis Rheum (2007) 1.14
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst (1996) 1.13
Fibronectin receptors of mononuclear phagocytes: binding characteristics and biochemical isolation. Exp Cell Res (1989) 1.11
Differentiation stimuli induce receptors for plasma fibronectin on the human myelomonocytic cell line HL-60. Blood (1984) 1.10
Plasma membrane polypeptides of resident and activated mouse peritoneal macrophages. Proc Natl Acad Sci U S A (1980) 1.10
Antibody-mediated cell cytotoxicity in a defined system: regulation by antigen, antibody, and complement. J Immunol (1976) 1.09
Preoperative embolization in surgical treatment of mediastinal hemangiopericytoma. Ann Thorac Surg (2000) 1.08
Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J Biol Chem (1997) 1.08
Expression of transforming growth factor alpha (TGF alpha) in breast cancer. Ann Oncol (1991) 1.08
Cripto-1 enhances migration and branching morphogenesis of mouse mammary epithelial cells. Exp Cell Res (2001) 1.05
Mortality of plastic-ware workers exposed to radiofrequencies. Bioelectromagnetics (1997) 1.04
Specific binding of the human monocytic cell line U937 to the alternatively spliced connecting segment (IIICS) of fibronectin. J Exp Med (1990) 1.04
Update of the follow-up of mortality and cancer incidence among European workers employed in the vinyl chloride industry. Epidemiology (2001) 1.03
The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res (2002) 1.02
[Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines]. Actas Urol Esp (2012) 1.02
The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther (2005) 1.02
Cripto-1 induces phosphatidylinositol 3'-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3beta in human cervical carcinoma cells. Cancer Res (1999) 1.00
The RIalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene (1997) 1.00
Mortality study of workers employed by the Italian National Institute of Health, 1960-1989. Scand J Work Environ Health (1992) 0.99
Screening of blood donors for idiopathic CD4+ T-lymphocytopenia. Transfusion (1994) 0.99
Age-dependent seroprevalence of Toscana virus in central Italy and correlation with the clinical profile. Clin Vaccine Immunol (2009) 0.99
Development of leiomyosarcoma of the uterus in MMTV-CR-1 transgenic mice. J Pathol (2007) 0.98
Detection of West Nile virus RNA and antibody in frozen plasma components from a voluntary market withdrawal during the 2002 peak epidemic. Transfusion (2005) 0.98
Deferral of males who had sex with other males. Vox Sang (2011) 0.98
Cancer risk among female agricultural workers: a multi-center case-control study. Am J Ind Med (1999) 0.97
RAS transformation causes sustained activation of epidermal growth factor receptor and elevation of mitogen-activated protein kinase in human mammary epithelial cells. Int J Cancer (2000) 0.97
Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res (1996) 0.97
Cripto-1 indirectly stimulates the tyrosine phosphorylation of erb B-4 through a novel receptor. J Biol Chem (1999) 0.97
Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 0.97
Purification, characterization, and functional role of a novel extracellular protease from Pleurotus ostreatus. Appl Environ Microbiol (2001) 0.96
EUROPLAN: a project to support the development of national plans on rare diseases in Europe. Public Health Genomics (2014) 0.96
Activation of C3H/HeJ macrophages by endotoxin. J Immunol (1980) 0.96
Septic sacroiliitis: an uncommon septic arthritis. Clin Exp Rheumatol (2010) 0.96
Fibrin, fibronectin, and macrophages. Ann N Y Acad Sci (1983) 0.95
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol (2011) 0.95
Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency. Ann Rheum Dis (2007) 0.95
[Pneumorachis associated with spontaneous pneumomediastinum. A case report]. Radiol Med (1997) 0.93
Asbestos-related lung cancer mortality in Piedmont, Italy. Am J Ind Med (1998) 0.93
Cripto-1 inhibits beta-casein expression in mammary epithelial cells through a p21ras-and phosphatidylinositol 3'-kinase-dependent pathway. Cell Growth Differ (1997) 0.92
Cancer mortality patterns among laboratory workers. Lancet (1990) 0.90
Local excision and external beam radiotherapy in early rectal cancer. Int J Radiat Oncol Biol Phys (1996) 0.90
Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. Oncogene (1994) 0.89
Transfusion-associated transmission of babesiosis in New York State. Transfusion (2000) 0.89
First cases of rubella infection during pregnancy detected by new reporting system in Italy. Euro Surveill (2006) 0.89
Allele *2 of the HS1,2A enhancer of the Ig regulatory region associates with rheumatoid arthritis. Ann Rheum Dis (2008) 0.88
Rationale for T cell inhibition by cyclosporin A in major autoimmune diseases. Ann N Y Acad Sci (2005) 0.88
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients. Clin Microbiol Infect (2012) 0.88
X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma. Clin Exp Immunol (2012) 0.87
The RI alpha subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. Oncogene (1994) 0.87
Phorbol ester-induced differentiation of U937 cells enhances attachment to fibronectin and distinctly modulates the alpha 5 beta 1 and alpha 4 beta 1 fibronectin receptors. Exp Cell Res (1991) 0.86
[The mortality among the makers of vinyl chloride in Italy]. Med Lav (1992) 0.86
Biobanks of blood from donors and recipients of blood products. Vox Sang (2008) 0.86
Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy. Eur J Clin Microbiol Infect Dis (2008) 0.85
Magnetic resonance imaging evaluation of myocardial perfusion. Am J Cardiol (1998) 0.85
mRNA expression of transforming growth factor alpha in human breast carcinomas and its activity in effusions of breast cancer patients. J Natl Cancer Inst (1989) 0.85
Localization of macrophage agglutination factor activity to the gelatin-binding domain of fibronectin. J Immunol (1984) 0.85